These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 34755627)

  • 1. Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study.
    Gonzales E; Hardikar W; Stormon M; Baker A; Hierro L; Gliwicz D; Lacaille F; Lachaux A; Sturm E; Setchell KDR; Kennedy C; Dorenbaum A; Steinmetz J; Desai NK; Wardle AJ; Garner W; Vig P; Jaecklin T; Sokal EM; Jacquemin E
    Lancet; 2021 Oct; 398(10311):1581-1592. PubMed ID: 34755627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maralixibat in progressive familial intrahepatic cholestasis (MARCH-PFIC): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Miethke AG; Moukarzel A; Porta G; Covarrubias Esquer J; Czubkowski P; Ordonez F; Mosca A; Aqul AA; Squires RH; Sokal E; D'Agostino D; Baumann U; D'Antiga L; Kasi N; Laborde N; Arikan C; Lin CH; Gilmour S; Mittal N; Chiou FK; Horslen SP; Huber WD; Jaecklin T; Nunes T; Lascau A; Longpre L; Mogul DB; Garner W; Vig P; Hupertz VF; Gonzalez-Peralta RP; Ekong U; Hartley J; Laverdure N; Ovchinsky N; Thompson RJ
    Lancet Gastroenterol Hepatol; 2024 Jul; 9(7):620-631. PubMed ID: 38723644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trial.
    Ovchinsky N; Aumar M; Baker A; Baumann U; Bufler P; Cananzi M; Czubkowski P; Durmaz Ö; Fischer R; Indolfi G; Karnsakul WW; Lacaille F; Lee WS; Maggiore G; Rosenthal P; Ruiz M; Sokal E; Sturm E; van der Woerd W; Verkade HJ; Wehrman A; Clemson C; Yu Q; Ni Q; Ruvido J; Manganaro S; Mattsson JP
    Lancet Gastroenterol Hepatol; 2024 Jul; 9(7):632-645. PubMed ID: 38670135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maralixibat Treatment Response in Alagille Syndrome is Associated with Improved Health-Related Quality of Life.
    Kamath BM; Goldstein A; Howard R; Garner W; Vig P; Marden JR; Billmyer E; Anderson A; Kirson N; Jacquemin E; Gonzales E
    J Pediatr; 2023 Jan; 252():68-75.e5. PubMed ID: 36096175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world experience of maralixibat in Alagille syndrome: Novel findings outside of clinical trials.
    Himes R; Rosenthal P; Dilwali N; Smith K; Venick R; Gonzalez-Peralta RP
    J Pediatr Gastroenterol Nutr; 2024 Mar; 78(3):506-513. PubMed ID: 38334237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of long-term administration of maralixibat on children with cholestasis secondary to Alagille syndrome.
    Shneider BL; Spino CA; Kamath BM; Magee JC; Ignacio RV; Huang S; Horslen SP; Molleston JP; Miethke AG; Kohli R; Leung DH; Jensen MK; Loomes KM; Karpen SJ; Mack C; Rosenthal P; Squires RH; Baker A; Rajwal S; Kelly D; Sokol RJ; Thompson RJ;
    Hepatol Commun; 2022 Aug; 6(8):1922-1933. PubMed ID: 35672955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maralixibat for the treatment of PFIC: Long-term, IBAT inhibition in an open-label, Phase 2 study.
    Loomes KM; Squires RH; Kelly D; Rajwal S; Soufi N; Lachaux A; Jankowska I; Mack C; Setchell KDR; Karthikeyan P; Kennedy C; Dorenbaum A; Desai NK; Garner W; Jaecklin T; Vig P; Miethke A; Thompson RJ
    Hepatol Commun; 2022 Sep; 6(9):2379-2390. PubMed ID: 35507739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Event-free survival of maralixibat-treated patients with Alagille syndrome compared to a real-world cohort from GALA.
    Hansen BE; Vandriel SM; Vig P; Garner W; Mogul DB; Loomes KM; Piccoli DA; Rand EB; Jankowska I; Czubkowski P; Gliwicz-Miedzińska D; Gonzales EM; Jacquemin E; Bouligand J; D'Antiga L; Nicastro E; Arnell H; Fischler B; Sokal É; Demaret T; Siew S; Stormon M; Karpen SJ; Romero R; Ebel NH; Feinstein JA; Roberts AJ; Evans HM; Sundaram SS; Chaidez A; Hardikar W; Shankar S; Fischer RT; Lacaille F; Debray D; Lin HC; Jensen MK; Jaramillo C; Karthikeyan P; Indolfi G; Verkade HJ; Larson-Nath C; Quiros-Tejeira RE; Valentino PL; Rogalidou M; Dezsőfi A; Squires JE; Schwarz K; Calvo PL; Bernabeu JQ; Zizzo AN; Nebbia G; Bulut P; Santos-Silva E; Fawaz R; Nastasio S; Karnsakul W; Tamara ML; Busoms CM; Kelly DA; Sandahl TD; Jimenez-Rivera C; Banales JM; Mujawar Q; Li LT; She H; Wang JS; Kim KM; Oh SH; Sanchez MC; Cavalieri ML; Lee WS; Hajinicolaou C; Lertudomphonwanit C; Waisbourd-Zinman O; Arikan C; Alam S; Carvalho E; Melere M; Eshun J; Önal Z; Desai DM; Wiecek S; Pinto RB; Wolters VM; Garcia J; Beretta M; Kerkar N; Brecelj J; Rock N; Lurz E; Blondet N; Shah U; Thompson RJ; Kamath BM;
    Hepatology; 2024 Jun; 79(6):1279-1292. PubMed ID: 38146932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Placebo-Controlled Randomized Trial of an Intestinal Bile Salt Transport Inhibitor for Pruritus in Alagille Syndrome.
    Shneider BL; Spino C; Kamath BM; Magee JC; Bass LM; Setchell KD; Miethke A; Molleston JP; Mack CL; Squires RH; Murray KF; Loomes KM; Rosenthal P; Karpen SJ; Leung DH; Guthery SL; Thomas D; Sherker AH; Sokol RJ;
    Hepatol Commun; 2018 Oct; 2(10):1184-1198. PubMed ID: 30288474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maralixibat: First Approval.
    Shirley M
    Drugs; 2022 Jan; 82(1):71-76. PubMed ID: 34813049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial.
    Thompson RJ; Arnell H; Artan R; Baumann U; Calvo PL; Czubkowski P; Dalgic B; D'Antiga L; Durmaz Ö; Fischler B; Gonzalès E; Grammatikopoulos T; Gupte G; Hardikar W; Houwen RHJ; Kamath BM; Karpen SJ; Kjems L; Lacaille F; Lachaux A; Lainka E; Mack CL; Mattsson JP; McKiernan P; Özen H; Rajwal SR; Roquelaure B; Shagrani M; Shteyer E; Soufi N; Sturm E; Tessier ME; Verkade HJ; Horn P
    Lancet Gastroenterol Hepatol; 2022 Sep; 7(9):830-842. PubMed ID: 35780807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, tolerability, and efficacy of maralixibat in adults with primary sclerosing cholangitis: Open-label pilot study.
    Bowlus CL; Eksteen B; Cheung AC; Thorburn D; Moylan CA; Pockros PJ; Forman LM; Dorenbaum A; Hirschfield GM; Kennedy C; Jaecklin T; McKibben A; Chien E; Baek M; Vig P; Levy C
    Hepatol Commun; 2023 Jun; 7(6):. PubMed ID: 37184523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study.
    Hegade VS; Kendrick SF; Dobbins RL; Miller SR; Thompson D; Richards D; Storey J; Dukes GE; Corrigan M; Oude Elferink RP; Beuers U; Hirschfield GM; Jones DE
    Lancet; 2017 Mar; 389(10074):1114-1123. PubMed ID: 28187915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resolution of Pruritus in a Child With Alagille Syndrome Treated With Maralixibat for Seven Years: Durable Response and Discontinuation of Other Medications.
    Garcia A; Hsu E; Lin HC
    JPGN Rep; 2023 Aug; 4(3):e335. PubMed ID: 37600618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial.
    Nakajima A; Seki M; Taniguchi S; Ohta A; Gillberg PG; Mattsson JP; Camilleri M
    Lancet Gastroenterol Hepatol; 2018 Aug; 3(8):537-547. PubMed ID: 29805116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of odevixibat on pruritus and bile acids in children with cholestatic liver disease: Phase 2 study.
    Baumann U; Sturm E; Lacaille F; Gonzalès E; Arnell H; Fischler B; Jørgensen MH; Thompson RJ; Mattsson JP; Ekelund M; Lindström E; Gillberg PG; Torfgård K; Soni PN
    Clin Res Hepatol Gastroenterol; 2021 Sep; 45(5):101751. PubMed ID: 34182185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Randomized, Controlled, Phase 2 Study of Maralixibat in the Treatment of Itching Associated With Primary Biliary Cholangitis.
    Mayo MJ; Pockros PJ; Jones D; Bowlus CL; Levy C; Patanwala I; Bacon B; Luketic V; Vuppalanchi R; Medendorp S; Dorenbaum A; Kennedy C; Novak P; Gu J; Apostol G; Hirschfield GM
    Hepatol Commun; 2019 Mar; 3(3):365-381. PubMed ID: 30859149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.
    Pivonello R; Fleseriu M; Newell-Price J; Bertagna X; Findling J; Shimatsu A; Gu F; Auchus R; Leelawattana R; Lee EJ; Kim JH; Lacroix A; Laplanche A; O'Connell P; Tauchmanova L; Pedroncelli AM; Biller BMK;
    Lancet Diabetes Endocrinol; 2020 Sep; 8(9):748-761. PubMed ID: 32730798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of 6-year event-free survival in Alagille syndrome patients treated with maralixibat, an ileal bile acid transporter inhibitor.
    Sokol RJ; Gonzales EM; Kamath BM; Baker A; Vig P; Mogul DB; Garner W; Hansen BE; Jacquemin E; Thompson RJ
    Hepatology; 2023 Dec; 78(6):1698-1710. PubMed ID: 37278241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum Bile Acid Profiling and Mixed Model Analysis Reveal Biomarkers Associated with Pruritus Reduction in Maralixibat-Treated Patients with BSEP Deficiency.
    Zhao X; Zhang W; Vig P; Kostrub C; Setchell KDR
    Metabolites; 2022 Oct; 12(10):. PubMed ID: 36295854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.